Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab

BACKGROUND: Rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of STAT3 plays an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yunfei, Ding, Ning, Jin, Xuan, Feng, Lixia, Ping, Lingyan, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007516/
https://www.ncbi.nlm.nih.gov/pubmed/24624997
http://dx.doi.org/10.1186/1475-2867-14-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007516/
https://www.ncbi.nlm.nih.gov/pubmed/24624997
http://dx.doi.org/10.1186/1475-2867-14-25

Ejemplares similares